Rectum and anus cancer Highligths Dott. Domenico Corsi UOC Oncologia Ospedale San Giovanni Calibita Fatebenefratelli Isola Tiberina
Focus on - Molecular variances between rectal and left-side colon cancer Slide 20 - International Watch and Wait Database in rectal cancer - Management of early low lying rectal cancer - New strategies in anal cancer Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Molecular Variances Between Rectal <br />and Left-Sided Colon Cancers Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Background Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
CONSORT Diagram Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Slide 20 Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Frequency of microsatellite instability in left-sided CRC Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Tumor Mutation Load (TML) Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Her2/Neu: Overexpression and Amplification Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Mutation Frequency Comparison Between Rectal and Right-sided Colon Cancers Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Her2/Neu : Overexpression and Amplification Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
Conclusions Presented By Mohamed Salem at 2017 Gastrointestinal Cancers Symposium
The International Watch & Wait Database (IWWD) for Rectal Cancer Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Watch & Wait in Rectal Cancer Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Slide 10 Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Slide 11 Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Slide 14 Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Slide 15 Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Slide 16 Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Cause of death Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Conclusion Presented By Maxime Valk at 2017 Gastrointestinal Cancers Symposium
Management of Low-Lying<br />Early Rectal Cancer Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Slide 6 Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Transabdominal Resection (TME) Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Consequences of transabdominal resection (TME) Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Local Excision (LE, TEM, TEO, TAMIS) Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Relative survival after local excision for T1 and T2 rectal cancer (Red Line) Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Nodal involvement by histopathology Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Options after LE: TME or ChemoRT Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Transabdominal resection (Completion TME) after LE<br />Technical Challenges Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Completion TME After LE - Results Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
Options after LE: TME or ChemoRT Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
ChemoRT before LE Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
RCT of endoluminal locoregional resection (ELRR) versus laparoscopic total mesorectal excision (TME)<br />for T2 rectal cancer after neoadjuvant therapy Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
ChemoRT and LE for T2N0 Rectal Cancer<br /> ACOSOG Z6041 Trial Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
ChemoRT and LE: ACOSOG Z6041 trial<br />Results for 72 Evaluable patients Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
SCRT and TEM for early rectal cancer Presented By Julio Garcia-Aguilar at 2017 Gastrointestinal Cancers Symposium
New strategies in Anal Cancer
Squamous cell carcinoma of the Anus<br />
Slide 11 Presented By Robert Glynne-Jones at 2017 Gastrointestinal Cancers Symposium
Squamous cell carcinoma of the anus Presented By Robert Glynne-Jones at 2017 Gastrointestinal Cancers Symposium
Rationale for Nivolumab in Metastatic SCCA: Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer <br /> Presented By Robert Glynne-Jones at 2017 Gastrointestinal Cancers Symposium
Slide 21 Presented By Robert Glynne-Jones at 2017 Gastrointestinal Cancers Symposium
Slide 24 Presented By Robert Glynne-Jones at 2017 Gastrointestinal Cancers Symposium
Published Regimens for Met Anal SCCA Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
KEYNOTE 028: Phase Ib Expanded cohort of Pembrolizumab Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
NCI9673: Phase II Design of Nivolumab in Metastatic SCCA Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
Patient Demographics Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
Primary Endpoint: Response Rate Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
NCI9673 Toxicities of Therapy Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium
NCI9673: PFS and OS Presented By Cathy Eng at 2017 Gastrointestinal Cancers Symposium